News
$1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle…
$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.
$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.
$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development. Fort…